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Abstract
Background: Menstrually related migraine (MRM) affects more than half of female migraineurs. Because such migraines are
often predictable, they provide a suitable target for treatment in the mild pain phase. The present study was designed to
provide prospective data on the efficacy of almotriptan for treatment of MRM.
Methods: Premenopausal women with MRM were randomized to almotriptan (N¼74) or placebo (N¼73), taken at
onset of the first perimenstrual migraine. Patients crossed over to the other treatment for the first perimenstrual
migraine of their second cycle, followed by a two-month open-label almotriptan treatment period.
Results: Significantly more patients were pain-free at two hours (risk ratio [RR]¼1.81; p¼.0008), pain-free from 2–24
hours with no rescue medication (RR¼1.99; p¼.0022), and pain-free from 2–24 hours with no rescue medication or
adverse events (RR¼1.94; p¼.0061) with almotriptan versus placebo. Nausea (p¼.0007) and photophobia (p¼.0083)
at twohours were significantly less frequent with almotriptan. Almotriptan efficacy was consistent between three attacks,
with 56.2% of patients pain-free at two hours at least twice. Adverse events were similar with almotriptan and placebo.
Conclusion: Almotriptan was significantly more effective than placebo in women with MRM attacks, with consistent
efficacy in longer-term follow-up.
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Introduction
Menstrually related migraine (MRM) aﬀects >50%
of female migraineurs, with <10% having migraines
exclusively in the perimenstrual period (PMP) (1).
The pathophysiology of MRM appears to involve an
abnormal neurotransmitter and neurohormonal
response, or abnormal release of prostaglandins trig-
gered by the cyclical drop of estrogen levels (2,3).
Neurobiological research suggests that activated central
sensory neurons may gradually become sensitized, lead-
ing to progression of pain and increasing sensitivity to
extracranial stimuli (4). These ﬁndings provide a path-
ophysiological rationale for treatment at the ﬁrst sign
of pain; as MRM is often predictable, it is an excellent
target for strategies initiated during the mild pain
phase.
Women with MRM may beneﬁt from short-term
prevention (5,6), but the condition is characterized by
a relatively low attack frequency. There is, therefore, a
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the beneﬁts of short-term preventive treatment. The
selective 5-hydroxytryptamine 1B/1D receptor agonists
(triptans) are generally the most eﬀective agents avail-
able (7) and may therefore be preferable for MRM in
view of its diﬃcult-to-treat nature (1).
In a retrospective analysis of data from women with
MRM from a randomized, comparative study of almo-
triptan versus zolmitriptan for acute treatment of
migraine, almotriptan was eﬀective and well tolerated
(8), while a post-hoc analysis of the placebo-controlled
AXERT Early Migraine Intervention Study (AEGIS)
study showed that almotriptan was similarly eﬀective in
MRM and non-MRM (9). To provide prospective data
on almotriptan in MRM, we conducted a randomized,
double-blind, placebo-controlled trial.
Methods
Objectives
The primary objective was to demonstrate the superi-
ority of almotriptan over placebo in the percentage of
patients free of pain two hours after drug intake during
an MRM attack. Secondary objectives were to investi-
gate the eﬃcacy and tolerability of almotriptan versus
placebo in women with MRM, and the consistency
of treatment with almotriptan during open-label
follow-up.
Study design
The study (EudraCT: 2005-000244-90) was a two-
month, multicenter, randomized, double-blind,
placebo-controlled crossover trial followed by a two-
month active treatment open-label follow-up evalua-
tion to assess consistency. The study was performed
in the neurology, headache or gynecology departments
at seven hospitals in Italy, in accordance with Good
Clinical Practice. The protocol was approved by the
ethics committees of all participating centers and writ-
ten informed consent was obtained from each patient.
Patients enrolled in the study attended the clinic for
ﬁve study visits, including the screening assessment.
Each visit other than the screening visit took place
two to six days after each migraine attack recorded in
the study. At each visit patients recorded migraine pain
intensity, adverse events and concomitant medications
in a diary.
Patients were randomized 1:1 to receive double-blind
oral almotriptan malate or identical, matching placebo.
Patients were assigned a randomization number in
ascending order by the Statistics Group within
Almirall SA., according to the relevant standard
operating procedure. The randomization list was
computer-generated, and randomization data were
kept strictly conﬁdential, accessible only by authorized
persons. Data were unblinded only when the trial was
completed and the data veriﬁed and locked. The success
of blinding was not formally evaluated during the study.
Study medication was self-administered at the onset
of the ﬁrst migraine attack occurring during the PMP
(deﬁned as day  2t oþ3 of the menstrual cycle).
Participants took one 12.5mg tablet, preferably in the
ﬁrst hour after pain onset or, if possible, when the pain
was still of mild intensity, and not more than two hours
after pain onset. Patients then crossed over to the other
double-blind treatment (almotriptan or placebo) for the
ﬁrst migraine in the PMP of their second menstrual
cycle. Two boxes (one box for the ﬁrst menstrual
migraine attack of one menstrual cycle and the other
for the ﬁrst menstrual migraine attack occurring in the
subsequent menstrual cycle) per patient were provided,
each containing two tablets of study medication or pla-
cebo in sealed blisters. One tablet was to be used for the
treatment of the attack, with the other to be used only
in case of recurrence. In the open-label phase, all
patients received almotriptan for the ﬁrst PMP
migraine in their third and fourth menstrual cycles.
Patients
Patients were almotriptan-naive women aged
18–50 years, from any ethnic group, who experienced
MRM, as deﬁned according to the criteria of the
International Headache Society (10). Patients were
required to have regular menstrual cycles, with at
least a one-year history of migraine and a six-month
history of regularly occurring MRM (migraine attacks
without aura, occurring on days  2t oþ3 of menstru-
ation in at least two of three menstrual cycles, with or
without additional attacks at other times of the cycle).
Participants were required to be in good general health,
and women of childbearing potential were required to
use an adequate form of contraception. Key exclusion
criteria included: any other type of headache that
would confound diagnosis of MRM; migraine head-
aches that did not typically have a mild pain phase,
that were typically associated with vomiting, or hemi-
plegic or basilar migraines; chronic daily headache
( 15 headache days per month for the previous six
months) or  6 migraines per month for the previous
three months; use of more than one medication (for any
reason) known to be eﬀective in migraine prophylaxis;
use of sustained-release opioids, or semisynthetic or
long-acting opioids, within seven days before study
entry; use of systemic or injectable corticosteroids
within 30 days before study entry; previous overuse
(>2 days per week) of analgesics, benzodiazepine sed-
ative hypnotics, antiemetics, triptans, opioids or
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ical disease or a history of a signiﬁcant mental disorder;
or a current or recent history, or suspected history, of
substance dependence or abuse. Lactating women were
also excluded from the study.
At baseline, patients were also required to provide a
veriﬁable diary of their migraine history covering at
least their preceding two menstrual cycles, their medical
history in general and their latest medication history.
Assessments
Headache pain intensity was rated by patients on a
4-point scale: (0¼no headache pain; 1¼mild headache
pain, allowing normal activity; 2¼moderate headache
pain, disturbing but not prohibiting normal activity,
bed rest is unnecessary; 3¼severe headache pain,
normal activity has to be discontinued, bed rest may
be necessary). Migraine-associated symptoms (nausea,
vomiting, phonophobia, photophobia, osmophobia),
migraine duration and use of rescue medication were
recorded throughout the study. Rescue medications
included nonsteroidal anti-inﬂammatory drugs and
paracetamol, and other agents that investigators con-
sidered to be appropriate for each patient at their
center. Triptans and ergotamine-containing drugs
were not permitted as rescue medication. Tolerability
was assessed in terms of adverse events, physical exam-
inations and vital signs.
Endpoints and analysis
According to sample size calculations, 130 evaluable
patients were required to demonstrate superiority of
almotriptan over placebo, and thus it was planned to
screen and randomize 160 patients to account for an
estimated 20% of withdrawals after randomization. A
sample size of 130 patients (pairs of observations)
achieves 90% power to detect an odds ratio (OR) of
2.00 using a two-sided McNemar test with a signiﬁ-
cance level of 0.05 and the proportion of patients free
of pain at two hours as primary endpoint. The OR is
equivalent to a diﬀerence between two paired propor-
tions of 0.250, which occurs when the proportion of
patients responding to almotriptan and not to placebo
is 0.500 and the proportion of patients responding to
placebo and not to almotriptan is 0.250. The propor-
tion of discordant pairs is 0.750.
The primary endpoint was the percentage of patients
free of pain at two hours after drug intake. Secondary
endpoints included percentage of patients pain-free at
time points from 0.25 to 24 hours after drug intake;
percentage of patients being sustained pain-free
(SPF; deﬁned as pain-free from 2 to 24 hours with no
rescue medication use); percentage of patients being
SPF with no adverse events (SNAE); rate of recurrence
(deﬁned as onset of a new attack within 24 hours of
successful drug treatment of the ﬁrst migraine attack);
percentage of patients with rescue medication intake;
evolution of migraine-associated symptoms (percentage
of patients with nausea, vomiting, phonophobia, pho-
tophobia or osmophobia 0.25–24 hours after study
drug intake).
The evaluation of primary endpoint and all the sec-
ondary endpoints, with the exception of ‘‘duration of
migraine attack’’, was performed by means of a gener-
alized linear model implemented with binomial distri-
bution, log-link function and generalized estimating
equations. The model eﬀects were treatment sequence
(almotriptan–placebo or placebo–almotriptan), treat-
ment (almotriptan or placebo) and the period (ﬁrst
and second). As this was a crossover study, a compound
symmetry variance–covariance matrix was employed to
account for clustered data (repeated measures).
Results were reported as RRs with the associated
95% conﬁdence interval (CI) and two-tailed p values.
The primary eﬃcacy population was the modiﬁed
intent-to-treat (mITT) population, deﬁned as all
patients who received at least one dose of study medi-
cation and for whom data on the primary endpoint
were available (i.e. double-blind phase completers).
A per-protocol analysis, from which patients with
major protocol violations were excluded, was also per-
formed. The safety population included all patients
who received at least one dose of study medication.
A post-hoc analysis was conducted to assess the eﬃcacy
of almotriptan in comparison with placebo in the sub-
groups of patients with pain of moderate/severe (inten-
sity score¼2 3) or mild (intensity score¼1) intensity
at headache onset.
Results
Patient disposition
The study was conducted between May 2005 and
October 2008. In total, 194 patients were screened, of
whom 147 were randomized to almotriptan–placebo
(ALM/PLA) (N¼74) or placebo–almotriptan (PLA/
ALM) (N¼73) (Figure 1). Of the 147 randomized
patients, 132 received at least one dose of study medi-
cation (ALM/PLA, N¼67; PLA/ALM, N¼65) and
were included in the safety analysis. Baseline character-
istics were similar in the two treatment arms; overall,
the mean (  standard deviation [SD]) age of patients
was 34.9 8.0 years, and all patients were Caucasian.
The double-blind phase was completed by 63/74
(85.1%) and 59/73 (80.8%) patients in the ALM/PLA
and PLA/ALM arms, respectively, and these patients
formed the mITT population (N¼122). The most
146 Cephalalgia 31(2)common reasons for withdrawal were loss to follow-up
(N¼8) and personal request (N¼5) (Figure 1). The
per-protocol population included 55 patients in each
treatment arm. The post-hoc analysis included 68
patients in the mild subgroup (almotriptan N¼36; pla-
cebo N¼32) and 176 in the moderate/severe subgroup
(almotriptan, N¼86; placebo N¼90).
Of the 122 patients who entered the open-label
phase, 105 (86.1%) completed the study. The most
common reason for withdrawal in the open-label
phase was loss to follow-up.
Efficacy — double-blind phase
Almotriptan was associated with a signiﬁcantly higher
percentage of patients free of pain at two hours after
drug intake compared with placebo (48.4% [N¼59/
122] vs. 26.2% [N¼32/122]; RR, 1.81 [95% CI,
1.28–2.57]; p¼.0008) (Table 1; Figure 2). The result
was conﬁrmed in the per-protocol population (49.1%
[N¼54/110] vs. 23.6% [N¼26/110]; RR, 2.02 [95%
CI, 1.37–2.99]; p¼.0004). In the post-hoc analysis,
Assessed for eligibility (n=194)
Screening failure (n=47)a
Randomised (n=147)
Almotriptan–placebo (n=74) Placebo–almotriptan (n=73)
Completed double-blind phase (n=63) Completed double-blind phase (n=59)
Early terminated (n=4)
Non-compliance: n=2
Lost to follow-up: n=1
Did not meet inclusion criteria: n=1
Early terminated (n=6)
Lost to follow-up: n=2
Personal request: n=1
Other reason: n=3
Did not receive study medication (n=8)
Personal request: n=4
Lost to follow-up: n=3
Other reason: n=3
Did not receive study medication (n=7)
Did not meet inclusion criteria: n=2
Lost to follow-up n=2
Other reason: n=3
Completed open-label phase (n=105)
Early terminated (n=17)b
aMost screening failures were because patients could not provide a verifiable diary of migraine covering their 
preceding menstrual cycles. Others refused for personal reasons; bMost patients who discontinued the open-label phase
did so for personal reasons or were lost to follow-up.
Figure 1. Patient disposition during the study.
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percentage of patients free of pain at twohours in the
mild subgroup (69.4% vs. 21.9%; p¼.0011) but not
in the moderate/severe subgroup (39.5% vs. 27.8%;
p¼.1100) (Table 1).
Overall, 36.1% of patients were classed as SPF while
receiving almotriptan, compared with 17.2% while
receiving placebo (p¼.0022); the result was also statis-
tically signiﬁcant in the moderate/severe subgroup
(29.1% vs. 15.6%; p¼.0268) but failed to achieve sig-
niﬁcance in the mild subgroup (52.8% vs. 21.9%;
p¼.0766) (Table 1). Similarly, almotriptan was associ-
ated with a signiﬁcantly higher percentage of patients
classed as SNAE compared with placebo (33.6% vs.
16.4%; p¼.0061) (Table 1). Again, this diﬀerence was
statistically signiﬁcant in the moderate/severe subgroup
(27.9% vs. 14.4%; p¼.0304) but not in the mild sub-
group (47.2% vs. 21.9%; p¼.2611).
During the double-blind phase, rescue medication
was used by 39.3% of patients (N¼48/122) while
receiving almotriptan and 59.8% (N¼73/122) while
receiving placebo (RR, 0.65 [95% CI, 0.52–0.83];
p¼.0004). In the mild and moderate/severe sub-
groups, the percentages were 33.3% (N¼12/36) vs.
59.4% (N¼19/32) (RR, 0.55 [95% CI, 0.33–0.92];
p¼0.0227) and 41.9% (N¼36/86) vs. 60.0% (N¼54/
90) (RR, 0.69 [95% CI, 0.52–0.91]; p¼.0078), respec-
tively. The duration of migraine attack was signiﬁ-
cantly shorter in patients receiving almotriptan
compared with placebo (7.5 vs. 10.8 hours; p¼.0170),
but was not signiﬁcantly diﬀerent between the two
treatment arms in either the mild or moderate/severe
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Figure 2. Percentage of patients pain-free at each time point after drug intake (modified intent-to-treat [mITT]population).
Table 1. Percentage of patients pain-free at 2 hours, SPF and SNAE
2 hours pain-free SPF SNAE
N %
RR
(95% CI) p value N %
RR
(95% CI) p value N %
RR
(95% CI) p value
All patients
Almotriptan (N¼122) 59 48.4 1.81
(1.28–2.57)
.0008 44 36.1 1.99
(1.28–3.09)
.0022 41 33.6 1.94
(1.21–3.13)
.0061
Placebo (N¼122) 32 26.2 21 17.2 20 16.4
Mild subgroup (post-hoc analysis)
Almotriptan (N¼36) 25 69.4 3.11
(1.58–6.14)
.0011 19 52.8 2.01
(0.93–4.36)
.0766 17 47.2 1.71
(0.67–4.39)
.2611
Placebo (N¼32) 7 21.9 7 21.9 7 21.9
Moderate/severe subgroup (post-hoc analysis)
Almotriptan (N¼86) 34 39.5 1.42
(0.92–2.18)
.1100 25 29.1 1.88
(1.08–3.30)
.0268 24 27.9 1.95
(1.07–3.57)
.0304
Placebo (N¼90) 25 27.8 14 15.6 13 14.4
SPF¼sustained pain-free (pain-free from 2–24 hours with no rescue medication). SNAE¼pain-free from 2–24 hours with no rescue medication or
adverse events. CI¼confidence interval; RR¼risk ratio.
148 Cephalalgia 31(2)subgroups (5.6 vs. 10.0 hours; p¼0.080 and 8.4 vs.
11.1 hours; p¼0.093, respectively) (Table 2).
Migraine recurrence within 24 hours of successful
treatment occurred in 28.8 % of patients (N¼17/59)
during almotriptan treatment and 31.3% (N¼10/32)
during placebo treatment (p¼.9349).
The incidence of nausea at two hours after drug
intake was signiﬁcantly lower while patients were
receiving almotriptan compared with placebo (19.0%
[N¼23/121] vs. 36.7% [N¼44/120]; RR, 0.52 [95%
CI, 0.36–0.76]; p¼.0007 [Wilcoxon rank-sum test]).
Similarly, the incidence of photophobia at two hours
post-medication (33.1% [N¼40/121] vs. 49.2%
[N¼59/120]; RR, 0.67 [95% CI, 0.50–0.90; p¼0.0083
[Wilcoxon rank-sum test]) was signiﬁcantly lower
during almotriptan treatment compared with placebo.
No between-group diﬀerences in vomiting, phonopho-
bia or osmophobia at two hours after drug intake were
reported.
Efficacy — open-label follow-up
During the open-label period, migraine data were avail-
able for the third migraine attack from 110 patients and
for the fourth migraine attack from 105 patients.
During the two menstrual cycles of the open-label
follow-up period, the percentage of patients pain-free
at two hours after medication intake in the mITT pop-
ulation was 55.5–59.0% (mild subgroup, 62.5–69.4%;
moderate/severe subgroup, 48.6–56.9%). The percent-
age ranged from 0.9–1.0% at 15 minutes post-intake to
64.8–71.8% at 24 hours. The percentages of patients
classed as SPF and SNAE were 40.0–41.8% and
36.2–39.1%, respectively (mild subgroup, 47.5–61.1%
and 45.0–55.6%; moderate/severe subgroup, 32.4–
35.4% and 30.8–31.1%). Rescue medication was used
by 17.1–17.3% of patients in the mITT population,
12.5–13.9% in the mild subgroup and 18.9–20.0% in
the moderate/severe subgroup. The eﬃcacy of almo-
triptan in terms of percentage of patients pain-free at
two hours, SPF, and SNAE was highly consistent
between the three attacks recorded in the study.
Overall, 59 of 105 patients (56.2%) responded to treat-
ment in at least two of three migraine attacks (i.e. were
pain-free at two hours post-intake at least twice out of
three attacks), while 42 (40.0%) and 39 (37.1%)
patients were SPF and SNAE, respectively, at least
twice out of three cycles.
The recurrence rate in the open-label phase was
29.5–33.9%. The incidence of migraine-associated
symptoms was generally numerically lower in the
open-label phase than in the double-blind phase.
At two hours after intake, the incidences were
nausea, 14.4–14.5%; vomiting, 1.0–2.7%; osmophobia,
1.8–3.8%; photophobia, 21.2–24.5%; and phonopho-
bia, 18.2–20.2%.
Safety
During the double-blind phase, treatment-emergent
adverse events (TEAEs) occurred in 8/132 patients
(6.1%) in the safety population during almotriptan
treatment and 8/132 patients (6.1%) during placebo
treatment. In the mITT population (N¼122), there
was no signiﬁcant diﬀerence in the incidence of
TEAEs between almotriptan and placebo (6.6% with
each treatment; RR, 1.03 [95% CI, 0.40–2.66];
p¼.9467). In the open-label phase, TEAEs were
reported in 9/132 patients (6.8%). Overall, 42% of
TEAEs were considered by the investigator to be deﬁ-
nitely, possibly, or probably related to the study drug.
All TEAEs were graded as mild or moderate, and none
led to study discontinuation during either study phase.
No individual TEAE was reported in >5% of patients,
Table 2. Mean duration (hours) of migraine attacks during double-blind treatment
Pain-free
Migraine duration (mean SD) Mean treatment difference (95% CI) p value
All patients
Almotriptan (N¼122) 7.5 10.1  3.3 ( 5.9;  0.6) .0170
Placebo (N¼122) 10.8 11.1
Mild subgroup (post-hoc analysis)
Almotriptan (N¼36) 5.6 9.2  4.4 ( 9.3; 0.5) .0801
Placebo (N¼32) 10.0 11.1
Moderate/severe subgroup (post-hoc analysis)
Almotriptan (N¼86) 8.4 10.4  2.7 ( 5.9; 0.5) .0933
Placebo (N¼90) 11.1 11.1
SD¼standard deviation. CI¼confidence interval.
Allais et al. 149and no serious adverse events or deaths were reported
during the study. No clinically relevant changes in vital
signs occurred within or between treatment arms.
Discussion
In this multicenter, double-blind, placebo-controlled,
randomized, crossover study, the superiority of almo-
triptan over placebo for MRM attacks was demon-
strated by the statistically signiﬁcantly higher
percentage of patients who were pain-free at two
hours after medication intake. This superiority was
also observed in patients with mild pain at headache
onset; the study was not powered to detect a diﬀerence
in patients with moderate/severe pain. In the open-label
follow-up phase (two further migraine attacks), the per-
centage of pain-free patients at two hours with almo-
triptan was maintained or even increased. Results for
secondary endpoints—including percentage of pain-free
patients over time, sustained freedom from pain with or
without adverse events, use of rescue medication and
occurrence of migraine symptoms—conﬁrmed the eﬃ-
cacy of almotriptan in the overall patient population.
Results in the post-hoc analyses of the mild and mod-
erate/severe subgroups also showed a beneﬁt for almo-
triptan, although some results did not achieve statistical
signiﬁcance. It should be noted, however, that the study
was not powered to detect diﬀerences between almo-
triptan and placebo in the post-hoc analyses.
The results of the present study are highly consistent
with those from a previous retrospective analysis of
almotriptan in women with MRM, in which 44.9% of
patients receiving almotriptan were pain-free at two
hours after medication intake (48.4% in the present
study), with a recurrence rate of 32.8% (28.8% in the
present study) (8). The results are also similar to those
of a post-hoc analysis of the randomized, placebo-con-
trolled AEGIS study, in which 35.4% of patients with
MRM and 35.9% of those with non-MRM were pain-
free at two hours post-medication, and 22.9% and
23.8%, respectively, were SPF (9).
In the present study, the safety and tolerability eval-
uations showed a similar proﬁle for almotriptan and
placebo, as has previously been observed both in
women with MRM (8,9) and in more general migraine
populations (11,12).
The main strengths of the present study are the ran-
domized, double-blind design and the adequate sample
size for the primary analysis, although there were insuf-
ﬁcient patients to draw deﬁnite conclusions in the post-
hoc analysis of mild and moderate/severe subgroups.
The patient population was suﬃciently broad to allow
generalization of the results to the wider population of
women with MRM, with only those with very frequent
or complicated (e.g. hemiplegic or basilar) migraine
excluded. One possible limitation of the study is the
analysis of treatment consistency, for which a more
individual intrapatient assessment may have been pre-
ferred. The present results do show, however, that 56%
of patients can be expected to respond to almotriptan
for at least two of three migraine attacks.
In conclusion, the results of this double-blind, pla-
cebo-controlled, crossover study demonstrated the eﬃ-
cacy of almotriptan in ameliorating the symptoms of
migraine and conﬁrmed its superiority over placebo in
women with MRM attacks, which are usually found to
be of longer duration and less responsive to acute treat-
ment than nonmenstrual attacks (13). Data from the
open-label follow-up phase corroborate those of the
double-blind phase and show the consistency of eﬀect
with almotriptan. Almotriptan was well tolerated
throughout the study, with an incidence of adverse
events similar to placebo. In light of its eﬃcacy and
tolerability proﬁle, almotriptan can be considered a
ﬁrst-choice acute treatment for women with MRM,
particularly if given during the mild pain phase of
migraines.
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